Effects of 1α-hydroxy-vitamin D 3 and 1,25-dihydroxy-vitamin D 3 on calcium and phosphorus metabolism in hypoparathyroidism

Abstract

The effects of 1α-OH D 3 or 1,25-(OH) 2D 3 on calcium and phosphorus metabolism have been evaluated in five hypoparathyroid patients to establish the direct effects of these compounds in adult humans, uncomplicated by compensatory changes in parathyroid hormone secretion. Doses of 1–2.5 μg/day in four patients (5 μg/day in a fifth patient on diphenyl-hydantoin and phenobarbital) caused a marked increase in serum calcium concentration and urinary calcium excretion, without significant changes in renal calcium clearance or urinary hydroxyproline excretion. These results suggest that the correction of hypocalcemia involved primarily a stimulation of intestinal calcium absorption rather than a stimulation of skeletal calcium resorption. Simultaneously, there were increases in urinary phosphorus excretion and variable changes in serum inorganic phosphate concentration. These effects were produced by doses of 1α-OH D 3 and 1,25-(OH) 2D 3 which approach the dose needed to prevent rickets, in contrast to the very large doses of vitamin D or 25-OH D 3 required for comparable effects in hypoparathyroid patients. The increased relative effectiveness of these one-hydroxylated forms of vitamin D reveals a deficiency of vitamin D one-hydroxylation in hypoparathyroidism. The rapidity of action of 1α-OH D 3 and 1,25-(OH) 2D 3 was also striking. Apart from its physiologic implications, the potency of the one-hydroxylated forms of vitamin D offers significant therapeutic advantages in some patients whose hypoparathyroidism is difficult to control with vitamin D itself.